94 related articles for article (PubMed ID: 30605831)
1. Discovery of potent, orally bioavailable ERK1/2 inhibitors with isoindolin-1-one structure by structure-based drug design.
Ji D; Zhang L; Zhu Q; Bai Y; Wu Y; Xu Y
Eur J Med Chem; 2019 Feb; 164():334-341. PubMed ID: 30605831
[TBL] [Abstract][Full Text] [Related]
2. Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
Heightman TD; Berdini V; Braithwaite H; Buck IM; Cassidy M; Castro J; Courtin A; Day JEH; East C; Fazal L; Graham B; Griffiths-Jones CM; Lyons JF; Martins V; Muench S; Munck JM; Norton D; O'Reilly M; Palmer N; Pathuri P; Reader M; Rees DC; Rich SJ; Richardson C; Saini H; Thompson NT; Wallis NG; Walton H; Wilsher NE; Woolford AJ; Cooke M; Cousin D; Onions S; Shannon J; Watts J; Murray CW
J Med Chem; 2018 Jun; 61(11):4978-4992. PubMed ID: 29775310
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
[TBL] [Abstract][Full Text] [Related]
5. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
6. A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer.
Cheng Y; Wang X; Xia X; Zhang W; Tian H
Int J Cancer; 2019 Jul; 145(2):586-596. PubMed ID: 30628057
[TBL] [Abstract][Full Text] [Related]
7. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
8. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
9. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
10. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
[TBL] [Abstract][Full Text] [Related]
13. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
14. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
16. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
17. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
Blake JF; Burkard M; Chan J; Chen H; Chou KJ; Diaz D; Dudley DA; Gaudino JJ; Gould SE; Grina J; Hunsaker T; Liu L; Martinson M; Moreno D; Mueller L; Orr C; Pacheco P; Qin A; Rasor K; Ren L; Robarge K; Shahidi-Latham S; Stults J; Sullivan F; Wang W; Yin J; Zhou A; Belvin M; Merchant M; Moffat J; Schwarz JB
J Med Chem; 2016 Jun; 59(12):5650-60. PubMed ID: 27227380
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
Ward RA; Anderton MJ; Bethel P; Breed J; Cook C; Davies EJ; Dobson A; Dong Z; Fairley G; Farrington P; Feron L; Flemington V; Gibbons FD; Graham MA; Greenwood R; Hanson L; Hopcroft P; Howells R; Hudson J; James M; Jones CD; Jones CR; Li Y; Lamont S; Lewis R; Lindsay N; McCabe J; McGuire T; Rawlins P; Roberts K; Sandin L; Simpson I; Swallow S; Tang J; Tomkinson G; Tonge M; Wang Z; Zhai B
J Med Chem; 2019 Dec; 62(24):11004-11018. PubMed ID: 31710489
[TBL] [Abstract][Full Text] [Related]
19. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
